Involvement of AMPK activation in the inhibition of hepatic gluconeogenesis by Ficus carica leaf extract in diabetic mice and HepG2 cells.
AMP-Activated Protein Kinases
/ metabolism
Animals
Diabetes Mellitus, Experimental
/ drug therapy
Dose-Response Relationship, Drug
Enzyme Activation
/ drug effects
Ficus
Gluconeogenesis
/ drug effects
Hep G2 Cells
Humans
Male
Mice
Mice, Inbred C57BL
Plant Extracts
/ isolation & purification
Plant Leaves
AMP-activated protein kinase
Diabetes mellitus
Ficus carica
Gluconeogenesis
Glucose-6-phosphatase
Phosphoenolpyruvate carboxykinase
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
06
2018
revised:
09
10
2018
accepted:
14
10
2018
pubmed:
6
11
2018
medline:
26
3
2019
entrez:
6
11
2018
Statut:
ppublish
Résumé
The aim of this study was to explore the possible mechanisms of Ficus carica leaf (FCL) extract in suppressing hepatic gluconeogenesis in diabetic mice. Diabetic mice (streptozotocin-induced) received 1 g/kg of FCL extract twice a day for 6 weeks. Fasting blood glucose levels were measured and a 2-h oral glucose tolerance test was conducted. AMP-activated protein kinase (AMPK), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), and peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) expression was examined. HepG2 hepatocytes were treated with FCL extract and an AMPK inhibitor (compound C) or agonist (AICAR), and PEPCK, G6pase, PGC-1α, AMPK, forkhead transcription factor O1 (FOXO1), and hepatic nuclear factor 4α (HNF4α) expression was determined. The results showed that FCL extract inhibited the expression of PEPCK and G6Pase in the liver of diabetic mice and HepG2 hepatocytes. FCL extract activated AMPK and decreased PGC-1α, HNF4α, and FOXO1 expression. The AMPK inhibitor attenuated those effects through inhibiting gluconeogenesis, while the AMPK agonist partially enhanced gluconeogenesis. In conclusion, FCL extract inhibits hepatic gluconeogenesis via activation of AMPK and down-regulation of gluconeogenic enzymes.
Identifiants
pubmed: 30396076
pii: S0753-3322(18)33996-9
doi: 10.1016/j.biopha.2018.10.077
pii:
doi:
Substances chimiques
Plant Extracts
0
AMP-Activated Protein Kinases
EC 2.7.11.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-194Informations de copyright
Copyright © 2018 Elsevier Masson SAS. All rights reserved.